Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
Product: Fasturtec
Active Ingredient: Rasburicase 1.5mg
Dosage Forms: Powder for infusion
Diluent
New Zealand Sponsor: Aventis Pharma Limited
Manufacturer: Glaxo Wellcome Production, Notre Dame de Bondeville, France
Note: This consent is valid for two years from 1 August 2006.
Dated this 13th day of July 2006.
DON MATHESON, Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on 6 July 2001).